Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463263 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
A Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell, sponsored by Step Pharma, SAS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
- 15
- Study locations
NCT05463263: Recruiting Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell, sponsored by Step Pharma, SAS.
NCT05463263 is a Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell that is actively recruiting participants, run by Step Pharma, SAS. The registered enrollment target is 180 participants, roughly in line with the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target. The trial reports 15 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463263, a Phase 1 study of Lymphoma, B-Cell and Lymphoma, T-Cell, is actively recruiting participants, sponsored by Step Pharma, SAS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
- 15
- Study locations
Study Summary
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Primary Outcome
Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs)
Conditions Studied
Interventions
- DRUG STP938
Study Locations (15)
Other
- The Centre Léon Bérard - Lyon
- Institut Paoli Calmettes - Marseille
- CHU de Nantes - Nantes
- Hôpital Saint-Louis - Paris
- Institut Gustave Roussy - Villejuif
- University Hospitals of Leicester NHS Trust - Leicester
- Imperial College / Clinical Trials Unit, Hammersmith Hospital - London
- The Christie - Manchester
- Nottingham City Hospital - Nottingham
- Churchill Hospital - Oxford
- Derriford Hospital - Plymouth
- The Royal Marsden - Sutton
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
New York
- Memorial Sloan Kettering - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT05463263 shows while recruiting
NCT05463263 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 196-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target.
The record links to 2 conditions, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 1 intervention - of which STP938 is the first listed.
NCT05463263 lists 15 locations in 4 states (Other, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT05463263 about?
NCT05463263 is a clinical study titled "A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas". The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
What is the current status of trial NCT05463263?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2022-08-03. Estimated completion is 2025-12.
What conditions does trial NCT05463263 study?
This clinical trial studies the following conditions: Lymphoma, B-Cell, Lymphoma, T-Cell.
What interventions are being tested in trial NCT05463263?
The interventions under investigation include: STP938 (DRUG).
Who is sponsoring clinical trial NCT05463263?
This trial is sponsored by Step Pharma, SAS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463263 being conducted?
This trial has 15 study locations across Colorado, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05463263's enrollment target sits among peer trials
180 7th of 31 higher than 25 of 31 other Lymphoma, B-Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, B-Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
RECRUITING · Phase 1
-
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RECRUITING · Phase 1
-
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI